Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| KPV | Sermorelin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation. | Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection. |
| Timing | Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous. | Bedtime administration (aligns with natural nocturnal GH release). On empty stomach. |
| Cycle Duration | 4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision. | 12-24 week cycles. Some protocols use continuous treatment. |
| Evidence Level | animal_plus_anecdotal | strong_human |
KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) that inhibits NF-kB signaling through a non-melanocortin receptor-mediated mechanism. It is transported intracellularly via the PepT1 transporter, where it stabilizes IkB-alpha and suppresses nuclear translocation of p65RelA by competing with importin-beta at the armadillo domain 7 and 8 binding site. It also reduces MAPK inflammatory signaling and IL-8 secretion in intestinal epithelial cells.
Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation.
Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous.
4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision.
Sermorelin is a synthetic 29-amino acid peptide representing the biologically active fragment of GHRH (amino acids 1-29) with full functional activity. It activates GHRH receptors on pituitary somatotrophs, stimulating cAMP production via Gs protein/adenylate cyclase and MAP kinase pathways. Due to the interactive effects of sermorelin and endogenous somatostatin, GH release is episodic rather than continuous. Sermorelin also stimulates pituitary gene transcription of GH mRNA, increasing and preserving pituitary GH reserve.
Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection.
Bedtime administration (aligns with natural nocturnal GH release). On empty stomach.
12-24 week cycles. Some protocols use continuous treatment.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →